Vancouver, British Columbia–(Newsfile Corp. – June 17, 2020) – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (“PreveCeutical”), is happy to announce that it has efficiently developed ‘Customary Working Procedures’ (“SOPs”) permitting for the chemical fingerprinting (profiling) of cannabinoids current in its extracts which can be utilized to formulate its proprietary Sol-gels for a wide range of potential therapeutic functions.
This is a crucial improvement enabling a standardized preparation of cannabinoid extracts infused sol-gel formulations, making certain strong cannabinoid chemistry profiling for various potential remedies to fulfill or exceed regulatory pointers. This may allow PreveCeutical and potential companions to quickly and persistently high quality management the chemical composition of cannabinoids from any given hashish/hemp pressure, by adoption of its SOPs.
Mr. Stephen Van Deventer, Chairman and CEO, commented, “Having established this SOPs for cannabinoid chemical fingerprinting permits us to attain precision, consistency and content material uniformity in cannabinoid Sol-gel formulations. Moreover, this SOPs will enable for extended managed dosage launch as required for particular remedies.”
PreveCeutical is a well being sciences firm that develops progressive choices for preventive and healing therapies using natural and nature equivalent merchandise.
PreveCeutical goals to be a frontrunner in preventive well being sciences. The Firm’s present analysis and improvement applications embody twin gene healing and preventive therapies for diabetes and weight problems; the Cannabidiols Sol-gel Program aiming to offer reduction throughout a spread of indications from ache, irritation, seizures, and neurological problems; Nature Equivalent™ peptides for the therapy of varied illnesses; non-addictive analgesic peptides as a alternative to the extremely addictive analgesics reminiscent of morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes that suffer from concussions (delicate traumatic mind damage).
On behalf of the Board of Administrators of PreveCeutical
Stephen Van Deventer, Chairman and Chief Govt Officer
For additional data, please contact:
Stephen Van Deventer at phone: +1 604 306 9669
Or Investor Relations [email protected]
This information launch accommodates forward-looking statements and forward-looking data (collectively, “forward-looking statements”) throughout the that means of relevant Canadian and U.S. securities laws, together with the USA Personal Securities Litigation Reform Act of 1995. All statements on this information launch that aren’t purely historic are forward-looking statements and embody any statements relating to beliefs, plans, expectations and orientations relating to the long run together with, with out limitation, the completion of the Sol-gel Program and the profitable improvement of CBD sol-gel formulations, and the continued analysis pursuits of PreveCeutical, PreveCeutical’s anticipated enterprise plans, and its prospects of success in executing its proposed plans. Usually, however not at all times, forward-looking statements will be recognized by phrases reminiscent of “will”, “professional forma”, “plans”, “expects”, “might”, “ought to”, “finances”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential”, “proposes” or variations of such phrases together with unfavorable variations thereof and phrases that seek advice from sure actions, occasions or outcomes that will, may, would, would possibly or will happen or be taken or achieved. Ahead-looking statements are primarily based on sure assumptions relating to PreveCeutical, together with anticipated progress, outcomes of operations, together with PreveCeutical’s analysis and improvement actions, efficiency, business tendencies, progress alternatives, that PreveCeutical might be granted requisite expedited approvals by world well being companies for the outcomes of the Sol-gel Program, and that PreveCeutical will have the ability to receive the financing required to additional perform or commercialize the Sol-gel Program, retain and entice certified analysis personnel and procure and/or keep the required mental property rights wanted to hold out future enterprise actions.
Precise outcomes may differ from these projected in any forward-looking statements because of quite a few elements together with, dangers and uncertainties referring to: complexities and delays in reference to analysis and improvement actions and the precise outcomes of analysis and improvement actions together with the profitable improvement of CBD sol-gel formulations; the flexibility of PreveCeutical to, amongst different issues, shield its respective mental property, receive any required governmental, regulatory or inventory trade approvals, permits, consents or authorizations required, together with Canadian Securities Trade acceptance of any deliberate future actions and acquiring expedited requisite approvals from world well being companies; and the flexibility of PreveCeutical to commercialize merchandise, pursue enterprise partnerships, full their analysis applications as deliberate, together with the Sol-gel Program, and procure the financing required to hold out their deliberate future actions. Different elements reminiscent of common financial, market or enterprise situations or modifications in legal guidelines, laws and insurance policies affecting the biotechnology or pharmaceutical business can also adversely have an effect on the long run outcomes or efficiency of PreveCeutical. These forward-looking statements are made as of the date of this information launch and, except required by relevant regulation, PreveCeutical assumes no obligation to replace the forward-looking statements or to replace the the explanation why precise outcomes may differ from these projected in these forward-looking statements. Though PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained on this information launch are cheap, there will be no assurance that these statements, beliefs, plans, expectations, or intentions will show to be correct. Readers ought to take into account all the data set forth herein and also needs to seek advice from different periodic reviews offered by PreveCeutical from time-to-time. These reviews and PreveCeutical’s filings can be found at www.sedar.com. Neither the Canadian Securities Trade (CSE or CNSX Markets), nor its Regulation Providers Supplier (as that time period is outlined in insurance policies of the CSE), or every other regulatory authority accepts accountability for the adequacy or accuracy of this launch.
Any hyperlink on this press launch to exterior data or different assets is offered for reference solely and such data or assets would possibly change every so often, and will embody forward-looking statements as described above, and are topic to the above disclaimers beneath this heading forward-looking statements.
Readers are cautioned that forward-looking statements will not be ensures of future efficiency or occasions and, accordingly, are cautioned to not put undue reliance on forward-looking statements because of the inherent uncertainty of such statements.
To view the supply model of this press launch, please go to https://www.newsfilecorp.com/release/58028